The NDA is based on results from REDEFINE 1, a 68-week, phase 3, randomised, double-blind, placebo-and active-controlled trial that evaluated the efficacy and safety of once-weekly, CagriSema compared to semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomised, placebo-controlled, 68-week, phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus placebo, as an adjunct to lifestyle intervention in 1,206 adults with type 2 diabetes and either obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2)
The complementary mechanisms of these compounds may support a more comprehensive neurological environment than any single peptide alone
10.3390/ph16020234 95 JiaC
5 (7) e006964
Recurrent attacks of acute gout often lead to chronic tophaceous gout, in which monosodium urate deposits (tophi) form in the soft tissues, usually along the rim of the ear, over the elbow joint, and in the joints of the fingers and toes
Indicatively, unlike the diclofenac plus L-arginine-, diclofenac plus L-NAME-, and diclofenac plus L-NAME plus L- arginine-treated rats, which showed no improvements, BPC 157 improved the diclofenac- induced adaptation as well as the additional impairment caused by L-NAME in all of the wall layers
